{"id":"W3097563180","doi":"10.3324/haematol.2020.261107","title":"Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)","year":2020,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Celgene; MorphoSys; F. Hoffmann-La Roche; Pharmacyclics; Genentech; Gilead Sciences; BeiGene; Sanofi; Servier; Amgen; Pfizer; GlaxoSmithKline","keywords":"Bendamustine; Ven; Tumor lysis syndrome; Medicine; Venetoclax; Tolerability; Obinutuzumab; Neutropenia; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Discontinuation; Rituximab; Leukemia; Toxicity; Chemotherapy; Lymphoma; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001447644,0.0007115839,0.001210433,0.0003458266,0.0002144661,0.0006283302,0.0005851923,0.0006488789,0.001724439],"category_scores_gemma":[0.0004820755,0.0003158772,0.0005108417,0.0003505814,0.0005406347,0.0004071629,0.0001766695,0.001664373,0.0003362553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006630146,"about_ca_system_score_gemma":0.0008009723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001313325,"about_ca_topic_score_gemma":0.003965016,"domain_scores_codex":[0.999667,0.0001856955,0.00001383022,0.0000367807,0.00002871861,0.0000679138],"domain_scores_gemma":[0.9996358,0.00008754997,0.00006166028,0.00002360226,0.00001660261,0.0001748282],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5585384,0.06975444,0.008020387,0.001310748,0.001338939,0.0004264137,0.000371194,0.003502094,0.1198088,0.0003472914,0.00371968,0.2328616],"study_design_scores_gemma":[0.3320285,0.6331796,0.01938095,0.0000719258,0.0006076575,0.0004731652,0.00005368643,0.001153023,0.00873213,0.0001496738,0.004139469,0.00003012179],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952343,0.0026983,0.0002073963,0.0001304306,0.00003326617,0.0003976099,0.0003499663,0.00004718365,0.0009015005],"genre_scores_gemma":[0.9926289,0.002756357,0.001010649,0.0002665891,0.00009531798,0.0004467206,0.001361066,0.00001891378,0.001415328],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001724439,"threshold_uncertainty_score":0.007655978,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1299696749944899,"score_gpt":0.3799866589269263,"score_spread":0.2500169839324364,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}